BTG, the specialist healthcare company, said it had outperformed in the first half and was boosting its revenue expectations for the full year.
The firm said is raising its revenue estimate for the year ending March 31st 2013 from £190m-£200m to £205m-£215m after a strong first half performance and a positive outlook for the second.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
It also saw a strong start from post-chemotherapy drug Voraxaze following its US nationwide launch at the end of April 2012
Among other products, it also noted the continued growth of royalties from Johnson & Johnson's prostate cancer drug Zytig.
First half revenue also included £5.4m of additional deferred income relating to a previous licence agreement that had been fully following AstraZeneca's decision axe development of CytoFab, nn experimental treatment for severe sepsis that failed in trials.
-
Steve Webb: The triple lock is there to do a job. I’m not embarrassed or ashamed of itThe triple lock means 13 million pensioners will now get an above-inflation state pension boost in April. While the rising cost of the policy has stirred controversy, Steve Webb, who served as pensions minister when it was introduced, argues the triple lock is vital and should stay. Webb speaks to Kalpana Fitzpatrick on the new episode of MoneyWeek Talks – out now.
-
How retirement pots risk running out 11 years early if inflation remains highPension savers could find their retirement income may not last as long as they anticipated over fears that inflation may not slow down
